HK1041832A1 - 血紅蛋白-抗氧化劑輟合物 - Google Patents

血紅蛋白-抗氧化劑輟合物

Info

Publication number
HK1041832A1
HK1041832A1 HK02103828.0A HK02103828A HK1041832A1 HK 1041832 A1 HK1041832 A1 HK 1041832A1 HK 02103828 A HK02103828 A HK 02103828A HK 1041832 A1 HK1041832 A1 HK 1041832A1
Authority
HK
Hong Kong
Prior art keywords
hemoglobin
conjugates
antioxidant
antioxidant conjugates
Prior art date
Application number
HK02103828.0A
Other languages
English (en)
Inventor
詹姆斯‧戈登‧亞當森
格雷格‧安格斯‧麥金托什
Original Assignee
赫姆索爾公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 赫姆索爾公司 filed Critical 赫姆索爾公司
Publication of HK1041832A1 publication Critical patent/HK1041832A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK02103828.0A 1999-03-18 2002-05-22 血紅蛋白-抗氧化劑輟合物 HK1041832A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002266174A CA2266174A1 (en) 1999-03-18 1999-03-18 Hemoglobin-antioxidant conjugates
PCT/CA2000/000299 WO2000056367A1 (en) 1999-03-18 2000-03-20 Hemoglobin-antioxidant conjugates

Publications (1)

Publication Number Publication Date
HK1041832A1 true HK1041832A1 (zh) 2002-07-26

Family

ID=4163391

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103828.0A HK1041832A1 (zh) 1999-03-18 2002-05-22 血紅蛋白-抗氧化劑輟合物

Country Status (10)

Country Link
US (1) US6974794B1 (zh)
EP (1) EP1163010B1 (zh)
JP (1) JP4739530B2 (zh)
KR (1) KR100676264B1 (zh)
AU (1) AU782407B2 (zh)
CA (2) CA2266174A1 (zh)
ES (1) ES2399835T3 (zh)
HK (1) HK1041832A1 (zh)
NZ (1) NZ513933A (zh)
WO (1) WO2000056367A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040005397A (ko) * 2002-07-10 2004-01-16 이대평 게르마늄 치환기를 가진 포르피린 유도체의 제조방법
CA2493748A1 (en) * 2002-08-14 2004-02-26 Medical College Of Georgia Research Institute, Inc. Methods and compositions for treatment of macular and retinal disease
MX2007010327A (es) * 2005-02-25 2007-10-16 Lilly Co Eli Inhibidores de lipoxigenasa novedosos.
US8609815B2 (en) 2010-09-02 2013-12-17 Sangart, Inc. Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant
JP7387597B2 (ja) 2017-07-18 2023-11-28 ヴァーテック・バイオ・インコーポレイテッド ヘモグロビンを含む代用血液及び作製方法
AU2019357737A1 (en) * 2018-10-12 2021-05-20 VirTech Bio, Inc. Oxygenation media for ex-vivo preservation of organs and tissues
KR102221365B1 (ko) * 2019-05-07 2021-03-02 (주)케어젠 트롤록스-펩타이드 결합체 및 그의 용도
CN111323606B (zh) * 2020-03-16 2021-08-10 中南大学 一种利用色素蛋白的氧化损伤检测抗氧化剂抗氧化效力的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4425334A (en) * 1982-04-02 1984-01-10 The Regents Of The University Of California Functional oxygen transport system
US4831012A (en) * 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
US5099012A (en) * 1990-12-11 1992-03-24 Eastman Kodak Company Chroman-2-carboxamide conjugates and their use for treatment of reperfusion injury
US5290919A (en) * 1992-08-28 1994-03-01 The University Of Maryland Baltimore Hemoglobin intramolecularly cross-linked with trivalent reagents
AU668294B2 (en) 1993-03-16 1996-04-26 Hemosol Inc. Selective crosslinking of hemoglobins by oxidized, ring-opened saccharides
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
FR2715582B1 (fr) * 1994-02-02 1996-03-15 Centre Nat Rech Scient Microcapsules à paroi de flavonoïde réticulée et compositions en contenant.
CA2135739C (en) * 1994-11-14 1997-10-21 Felice D'agnillo Hemoglobin-enzyme complexes
ATE193007T1 (de) * 1995-06-16 2000-06-15 Ronald Kluger Multifunktionelle vernetzungsreagenzien für haemoglobin und vernetzte haemoglobinconjugate
WO1998034955A1 (en) * 1997-02-06 1998-08-13 Duke University Medical Center No-modified hemoglobins and uses therefor
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes

Also Published As

Publication number Publication date
AU3269000A (en) 2000-10-09
JP2002540081A (ja) 2002-11-26
EP1163010B1 (en) 2012-12-12
CA2366833C (en) 2010-06-15
ES2399835T3 (es) 2013-04-03
AU782407B2 (en) 2005-07-28
US6974794B1 (en) 2005-12-13
KR20010111571A (ko) 2001-12-19
WO2000056367A1 (en) 2000-09-28
CA2366833A1 (en) 2000-09-28
NZ513933A (en) 2001-09-28
EP1163010A1 (en) 2001-12-19
KR100676264B1 (ko) 2007-01-30
CA2266174A1 (en) 2000-09-18
JP4739530B2 (ja) 2011-08-03

Similar Documents

Publication Publication Date Title
DE60018571D1 (en) Hernienprothese
DE60008112D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
HUP0300548A3 (en) Polyol-ifn-betha conjugates
DE60008382D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE50002490D1 (en) Polyester-polyetherblockcopolymere
DE50008011D1 (en) Thixotropierungsmittel
DE60018288D1 (en) Polyphenylensulfidlegierungszusammensetzung
DE60027722D1 (en) Aspartyl-protease inhibitoren
DE50002614D1 (en) Sigma-delta-modulator
DE60028360D1 (en) Ptk-chipthermistor
DE60011809D1 (en) Oxcarbazepinsuspension
DE50000137D1 (en) Spirofluorenopyrane
DE59909975D1 (en) Testleck
DE10081629D2 (en) Seilzugbefestigung
DE60001313D1 (en) Imidazodiazepinderivate
DE60012950D1 (en) Polyacetalharzzusammensetzung
DE50009469D1 (en) Common-rail-injektor
HK1041832A1 (zh) 血紅蛋白-抗氧化劑輟合物
DE50010757D1 (en) Stilbenaufheller
HK1046280B (zh) 1-三氟甲基-4-羥基-7-哌啶基-氨甲基苯並二氫吡喃衍生物
DE60026282D1 (en) Photovervielfacherröhre
DE50008218D1 (en) Common-rail-injektor
DE50012999D1 (en) Stirnwandisolation
DE60004080D1 (en) Centroidintegration
DE60012212D1 (en) Orthotopisches totalkunstherz